Novel form of S-omeprazole

• US 20050075369A1
• Filed: 09/25/2003
• Published: 04/07/2005
• Est. Priority Date: 05/30/1997
• Status: Active Grant

• Current Assignee: Anders Kronstrom, Anders Mattson, Eva Moller, Hanna Cotton
• Original Assignee: Anders Kronstrom, Anders Mattson, Eva Moller, Hanna Cotton
• Inventors: Cotton, Hanna, Mattson, Anders, Moller, Eva, Kronstrom, Anders
• Granted Patent: US 7,411,070 B2
• Time in Patent Office: Days
• US Class Current: 514/338
• CPC Class Codes: A61P 1/04 for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
• CPC Class Codes: A61P 17/06 Antipsoriatics
• CPC Class Codes: A61P 31/04 Antibacterial agents
• CPC Class Codes: C07D 401/12 linked by a chain containing hetero atoms as chain links

Abstract

The present invention relates to a novel form of the (−)-enantiomer of 5-methoxy-2[[(4-methoxy-3,5-dimethyl-2-pyridinyl)-methyl]sulfinyl]-1H-benzimidazole, i.e. S-omeprazole. More specifically, it relates to a novel form of the magnesium salt of the S-enantiomer of omeprazole trihydrate. The present invention also relates to processes for preparing such a form of the magnesium salt of S-omeprazole and pharmaceutical compositions containing it. Furthermore, the present invention also relates to new intermediates used in the process.

Claims

1. The magnesium salt of S-omeprazole trihydrate.

2. The magnesium salt of S-omeprazole trihydrate according to claim 1, wherein the compound is in a highly crystalline form.

14. A pharmaceutical composition comprising the magnesium salt of S-omeprazole trihydrate according to claim 1 or 2 as active ingredient in association with a pharmaceutically acceptable carrier.

17. The pharmaceutical composition according to claim 14 further comprising one or more therapeutically active ingredients.

18. A method of treating a gastric acid related condition which method comprises administering to a subject suffering from said condition a therapeutically effective amount of the magnesium salt of S-omeprazole trihydrate according to claim 1 or 2.

3-13. -13. (canceled)

15-16. -16. (canceled)